The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health

by Robert F. Kennedy Jr.

Eric Topol of Scripps Research Translational Institute scolded that, “This is a very, very bad look for the FDA, and the dealings between Gilead and EU make it another layer of badness.”63 Angela Rasmussen, a virologist at Columbia University Mailman School of Public Health, told a reporter: “I was really surprised when I saw that news.”64 Science Magazine said Dr. Fauci’s move had, “baffled scientists who have closely watched the clinical trials of remdesivir unfold over the past 6 months—and who have many questions about remdesivir’s worth.”65 University of Oxford Professor of Clinical Therapeutics Duncan Richard scathingly observed that, “Research based on this kind of use should be treated with extreme caution because there is no control group or randomization, which are some of the hallmarks of good practice in clinical trials.”66 Professor Stephen Evans in Pharmacoepidemiology, at the Gates-funded London School of Hygiene & Tropical Medicine, offered a particularly scathing assess-ment—“The data from this paper are almost uninterpretable. It is very surprising, perhaps even unethical, that the New England Journal of Medicine has published it. It would be more appropriate to publish the data on the website of the pharmaceutical company that has sponsored and written up the study. At least Gilead has been clear that this has not been done in the way that a high-quality scientific paper would be written.”67